355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
Nina Shah(The University of Texas MD Anderson Cancer Center), Krina K. Patel(University of Vermont), Takahiro Miyazaki(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Craig C. Hofmeister(The Ohio State University), Xue Ge(Nektar Therapeutics (United States)), Gregory Orloff(Virginia Cancer Specialists), Hayder Saeed(University of Kentucky), Loui Madakamutil(Nektar Therapeutics (United States)), Mario Q. Marcondes(Nektar Therapeutics (United States)), Mona Vimal(Nektar Therapeutics (United States)), David A. Rizzieri(Duke University), Mary Tagliaferri(Nektar Therapeutics (United States)), Alan Tan(Unknown), Lihua E. Budde(City Of Hope National Medical Center), Wei Lin(Nektar Therapeutics (United States)), Andrew J. Cowan(University of Washington), Zachary Lee(Nektar Therapeutics (United States)), Jing Ye(Soochow University), Neha Dixit(Nektar Therapeutics (United States)), Mitchell S. Cairo(New York Medical College), Haijun Ma(Nektar Therapeutics (United States)), Wildaliz Nieves(Nektar Therapeutics (United States))
Cited by 3
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695